Article info

Download PDFPDF

Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19
Free

Authors

  1. Correspondence to Christian Skalafouris, Pharmacy, Geneva University Hospitals, 1205 Geneva, Switzerland; christian.skalafouris{at}hcuge.ch
View Full Text

Citation

Skalafouris C, Samer C, Stirnemann J, et al
Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19

Publication history

  • Received December 23, 2020
  • Revised March 2, 2021
  • Accepted March 9, 2021
  • First published April 8, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.